DH
Definitive Healthcare Corp.2.2900
-0.0100-0.44%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Retention cohorts improve; NDR bottoms
Q&A surfaced granular retention progress, with post-Q1'24 cohorts up 200bps and Q4 integrations accelerating to 60 new customers versus 160 yearly. Enterprise life sciences bolstered gross dollar retention gains, while diversified and provider—60% of revenue—posted Q4 growth offsetting life sciences downsells. Management pegged 2025 as NDR bottom, guiding modest 2026 uplift amid claims remediation and AI tailwinds, though fall data pack missed Q4 renewals for Q1/Q2 impact. Analysts grilled end-markets and AI risks; replies stayed confident, no hedges. Green shoots abound. Investors watch NDR trajectory closely.
Key Stats
Market Cap
238.36MP/E (TTM)
-Basic EPS (TTM)
-1.72Dividend Yield
0%Recent Filings
8-K
Q4 revenue dips, margins hold
Definitive Healthcare reported Q4 2025 revenue of $61.5M, down 1% from prior year yet hitting guidance highs, with Adjusted EBITDA rising to $18.0M or 29% margin. Full-year revenue fell to $241.5M amid $196.1M goodwill impairments, but cash from operations hit $53.8M. Q1 2026 revenue guides $54-56M; full-year $220-226M. Retention drives recovery.
10-K
FY2025 results
Definitive Healthcare's FY2025 revenue fell 4% y/y to $241.5M, driven by sales execution disruptions from 2024 restructuring and macroeconomic headwinds elongating deal cycles, though Q4 showed modest demand stabilization. Enterprise NDR slipped to 85% from 90%, with customer count dropping to 2,330 amid elevated churn in Life Sciences and smaller accounts, yet cRPO held at $240M. Gross margin contracted to 76% on fixed costs and data renegotiations; Adjusted EBITDA dipped to $70M (29% margin). Debt stands at $166M with $50M revolver availability; $49M stock buybacks executed. Q4 momentum hints at renewal uptick. Data provider disruptions risk quarterly cost spikes.
8-K
Q3 revenue dips, profitability holds
Definitive Healthcare reported Q3 revenue of $60.0M, down 4% from $62.7M last year, yet narrowed net loss to $17.8M from $187.8M after prior goodwill hit. Adjusted EBITDA held at $18.9M or 32% margin, with operations cash flow at $15.7M. New biopharma and med device wins signal retention gains. Q4 revenue guided $59-60M; full-year raised to $239-240M.
10-Q
Q3 FY2025 results
Definitive Healthcare's Q3 revenue dipped 4% y/y to $60.0M while gross profit held at 77%—revenue from prior customers fell $9.4M, offset by $6.7M from new ones. Operating loss narrowed sharply to $8.7M from $225.4M, sans last year's $228.2M goodwill hit; net loss attributable to Class A improved to $(0.14) per share on 103.8M diluted shares. Cash flow stayed solid at $51.1M YTD operating cash, with $108.3M cash, $77.6M short-term investments, and $49.7M revolver availability against $166.9M term debt (due 2030). Repurchased $49.5M in shares YTD. Stock price drops trigger impairment risks.
10-Q
Q2 FY2025 results
Definitive Healthcare's Q2 revenue dipped 5% year-over-year to $60.8M, with subscription services down amid sales disruptions and macroeconomic pressures, yet professional services rose 46% to $2.6M. Gross profit held at 77% margin, while operating loss narrowed sharply to $4.2M from $369.6M, thanks to no repeat of last year's massive goodwill impairment. Adjusted EBITDA came in at $18.7M, or 31% margin, edging lower from 33% but signaling cost discipline. Cash and equivalents stood at $81.0M, bolstered by $35.4M in operating cash flow for the half-year, with $49.7M revolver availability and term debt at $169.0M after $73.4M repayments. The Carevoyance asset buy closed in January 2024 for $13.7M cash, adding $7.1M goodwill and intangibles amortized over 6.9 years. Sales execution hiccups linger as a key risk.
IPO
Website
Employees
Sector
Industry
CMHSF
COMPREHENSIVE HEALTHCARE SYS IN
0.35+0.00
DRIO
DarioHealth Corp.
12.05+0.05
FORA
Forian Inc.
2.14+0.00
HCTI
Healthcare Triangle, Inc.
2.09-0.18
HSTM
HealthStream, Inc.
23.91-0.47
PHR
Phreesia, Inc.
16.35-0.35
RMHI
Retrieve Medical Holdings Inc
2.82+0.02
SOPH
SOPHiA GENETICS SA
4.81+0.09
VEEV
Veeva Systems Inc.
219.30-0.80
WORX
SCWorx Corp.
0.21-0.01